COVID-19 treatments: under evaluation
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA’s CHMP is evaluating the following COVID-19 treatments:
|Treatment||Treatment developer||Key milestones||More information|
|REGN-COV2 antibody combination (casirivimab / imdevimab)||Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd (Roche)||
Start of rolling review: 01/02/2021
|Monoclonal antibody regdanvimab||Celltrion||Start of rolling review: 24/02/2021||EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19|
|Monoclonal antibodies bamlanivimab and etesevimab||Eli Lilly||Start of rolling review: 11/03/2021||EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19|